Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
Authors:
Open Access
- 14 November 2014
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 55 (2) , 230-239
Abstract
Ceftolozane/tazobactam is a novel antipseudomonal cephalosporin and β-lactamase inhibitor in clinical development for treatment of complicated urinary tract (cUTI) and intra-abdominal (cIAI) infections and nosocomial pneumonia. The population pharmacokinetics of ceftolozane/tazobactam were characterized in healthy volunteers, subjects with varying degrees of renal function, and patients with cIAI or cUTI. Serum concentration data from 376 adults who received ceftolozane/tazobactam in doses ranging from 500 to 3000 mg were analyzed to identify factors contributing to the pharmacokinetic variability. Ceftolozane/tazobactam pharmacokinetics were well described by a linear two-compartment model with first-order elimination and moderate between-subject variability in both clearance and volume of distribution (Vc). For both ceftolozane and tazobactam, clearance was highly correlated with renal function with creatinine clearance influencing exposure, and infection influencing Vc. Body weight was an additional covariate affecting the Vc of ceftolozane. Other covariates tested, such as age, body weight, sex, ethnicity, and presence of infection, had no clinically relevant effects on exposure. The final pharmacokinetic models adequately described the plasma concentrations of ceftolozane and tazobactam and form the basis for further modeling and simulation including evaluation of probability of target attainment in a diverse population with varying demographics, degrees of renal function, and infection status.Keywords
This publication has 20 references indexed in Scilit:
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal InfectionsAntimicrobial Agents and Chemotherapy, 2014
- Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)Journal of Infection, 2014
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-TazobactamAntimicrobial Agents and Chemotherapy, 2014
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with CeftolozaneAntimicrobial Agents and Chemotherapy, 2013
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)Antimicrobial Agents and Chemotherapy, 2013
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection ModelAntimicrobial Agents and Chemotherapy, 2013
- How should we dose antibiotics for pneumonia in the ICU?Current Opinion in Infectious Diseases, 2013
- In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic MiceAntimicrobial Agents and Chemotherapy, 2013
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjectsJournal of Antimicrobial Chemotherapy, 2012
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending DosesAntimicrobial Agents and Chemotherapy, 2012